Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2019 0 · FY2020 0 · FY2021 0
Operates in Pharma — Production. Per the activity note to the FY2024 annual report, the company manufactures pharmaceutical preparations.
Subsidiary of Shezghuduli Pasukhismgeblobis Sazogadoeba LLC Geo Holding (100.0%)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 4,234 | 7,022 | 7,406 | 5,460 | 10,596 | 12,756 | 6,488 | +7.4% | |
| Total COGS | 1,232 | 2,020 | 2,544 | 1,421 | 4,397 | 5,310 | 2,854 | +15.0% |
| Gross Profit | 3,002 | 5,002 | 4,863 | 4,039 | 6,199 | 7,446 | 3,634 | +3.2% |
| Gross Margin | 70.9% | 71.2% | 65.7% | 74.0% | 58.5% | 58.4% | 56.0% | |
| 738 | 1,162 | 5,611 | 2,536 | 2,567 | 4,042 | 1,737 | +15.3% | |
| EBITDA | 2,263 | 3,840 | 748 | 1,503 | 3,632 | 3,405 | 1,897 | -2.9% |
| EBITDA Margin | 53.5% | 54.7% | 10.1% | 27.5% | 34.3% | 26.7% | 29.2% | |
| Total D&A | 20 | 17 | 22 | 27 | 29 | 83 | 0 | +32.4% |
| EBIT / Operating Income | 2,243 | 3,823 | 770 | 1,476 | 3,603 | 3,321 | 1,897 | -2.8% |
| Total Interest Income | 0 | 519 | 218 | 11 | 46 | 40 | 0 | -47.4% |
| Total Interest Expense | 0 | 246 | 0 | 0 | 0 | 0 | 0 | |
| 31 | 0 | 36 | 81 | 781 | 1 | 365 | nmf | |
| Profit Before Tax | 2,274 | 4,096 | 516 | 1,406 | 2,868 | 3,361 | 1,532 | -6.4% |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 2,298 | 4,077 | 516 | 1,422 | 2,868 | 3,361 | 1,532 | -6.5% |
| Net Margin | 54.3% | 58.1% | 7.0% | 26.0% | 27.1% | 26.3% | 23.6% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.